

Amendments to the Claims

Please cancel Claim(s) 2, 31, 32, and 44 . Please amend Claim(s) 1, 3-4, 28-29, 33-34 and 41-42. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended): A method of delivering a moiety of interest into a cell, the method ~~comprising contacting the cell with~~ comprising:

(a) providing a complex comprising the moiety of interest covalently linked to a protein consisting of a portion of a heat shock protein (hsp), wherein the cell is contacted the amino terminal ATP binding domain of a heat shock protein 70 (hsp70) or the carboxyl terminal peptide binding domain of an hsp70 and

(b) contacting the cell with the complex under conditions appropriate for entry of the complex into the cell ~~and the portion of the hsp is sufficient to deliver the moiety into the cell.~~

2. (Canceled)

3. (Currently amended): The method of claim [2] 1, wherein the ~~heat shock protein~~ hsp70 is a mycobacterial hsp70.

4. (Currently amended): The method of claim 1, wherein the moiety of interest is a protein or a peptide.

5. (Previously presented): The method of claim 1, wherein the cell is an antigen presenting cell.

6. (Withdrawn): The method of claim 1, wherein the heat shock protein is a yeast heat shock protein, a bacterial heat shock protein, a mammalian heat shock protein, an insect heat shock protein, or a fungal heat shock protein.

7. (Withdrawn): The method of claim 2, wherein the heat shock protein is an hsp65, hsp60, hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 or hsp100-200.

8. (Previously presented): The method of claim 4, wherein the protein or peptide is glycosylated.

9-24. (Canceled).

25. (Withdrawn): The method of claim 1, wherein the moiety comprises a lipid, carbohydrate, or small organic molecule.

26. (Withdrawn): The method of claim 6, wherein the mammalian heat shock protein is a human heat shock protein.

27. (Previously presented): The method of claim 1, wherein the cell is a human cell.

28. (Currently amended): The method of claim 1, wherein the moiety of interest is covalently linked to the ~~heat shock protein~~ hsp70 by a peptide bond.

29. (Currently amended): The method of claim 1, wherein the moiety of interest is covalently linked to the ~~heat shock protein~~ hsp70 by chemical conjugation.

30. (Previously presented): The method of claim 1, wherein the cell is a cell *in vivo*.

31-32. (Canceled)

33. (Currently amended): The method of claim 5, wherein the ~~heat shock protein~~ hsp70 is a mycobacterial hsp70.

34. (Currently amended): The method of claim 5, wherein the moiety of interest is a protein or peptide.

35. (Withdrawn): The method of claim 5, wherein the heat shock protein is a yeast heat shock protein, a bacterial heat shock protein, a mammalian heat shock protein, an insect heat shock protein, or a fungal heat shock protein.

36. (Withdrawn): The method of claim 32, wherein the heat shock protein is an hsp65, hsp60, hsp71, hsp90, hsp100, hsp10-12, hsp20-30, hsp40 or hsp100-200.

37. (Previously presented): The method of claim 34, wherein the protein or peptide is glycosylated.

38. (Withdrawn): The method of claim 5, wherein the moiety comprises a lipid, carbohydrate, or small organic molecule.

39. (Withdrawn): The method of claim 35, wherein the mammalian heat shock protein is a human heat shock protein.

40. (Previously presented): The method of claim 5, wherein the antigen presenting cell is a human antigen presenting cell.

41. (Currently amended): The method of claim 5, wherein the moiety of interest is covalently linked to the ~~heat shock protein~~ hsp70 by a peptide bond.

42. (Currently amended): The method of claim 5, wherein the moiety of interest is covalently linked to the ~~heat shock protein~~ hsp70 by chemical conjugation.

43. (Previously presented): The method of claim 5, wherein the cell is a cell *in vivo*.

44. (Canceled)